PROJECT SUMMARY/ABSTRACT During the current project period, Developmental Funds have been essential to maintain and extend the reach and vitality of the scientific Programs in the Sidney Kimmel Comprehensive Cancer Center (SKCCC). Specific aims of the SKCCC Developmental Funds are: Aim 1: To recruit cancer researchers in the strategic areas of need. Aim 2: To support staff investigators who are critical to the activities of the SKCCC. Use of these funds is closely tied to the SKCCC strategic plan, Innovation for Impact 2025. The funds have been used to build scientific strength in a number of Research Programs, including: 1) recruiting new investigators to build laboratory research capability across the SKCCC Research Programs and 2) recruiting underrepresented minority (URM) faculty members. During the current project period, 16 new investigators were recruited using $250,000 per year from Developmental Funds, including nine women and five URMs. Fifty-one new externally funded grants were awarded to these new investigators ($6.04 million annual direct costs which, gave a return on investment of 24 to 1), and another twelve grants are pending with an impact of over $3.1 million annual direct costs. A total of 128 peer-reviewed articles were published by new investigators. Developmental Funds for Shared Resources (SRs) were also used to support the Translational Research Central Services SR, which is a fully established SR in this renewal application. In addition, although CCSG Developmental Funds were not used, the SKCCC Intramural Grant Program funding resulted in $4.98 million direct costs extramural grants annually, including 13 National Cancer Institute R01s, four other NIH R01s, four U01s, four R21s, two K Awards, one U54 Project and six PPG Projects. It has also resulted in 152 publications, 14 new clinical trials and 19 patents. Developmental Funds are requested to continue new investigator recruitment and provide support to staff investigators.